申请人:Dainippon Pharmaceutical Co., Ltd.
公开号:US04870074A1
公开(公告)日:1989-09-26
Compounds of the formula: ##STR1## wherein R is hydrogen, alkoxycarbonyl, benzyloxycarbonyl, heteroarylalkyl, phenylalkenyl, or --T--(Y).sub.p --R.sub.6 (wherein T is single bond or alkylene, Y is oxygen, sulfur or carbonyl, R.sub.6 is phenyl, substituted phenyl, naphthyl, or diphenylmethyl, and p is 0 or 1, provided that when T is single bond, p is 0); R.sub.1 is halogen, hydroxy, alkoxy, cycloalkyloxy, alkenyloxy, alkynyloxy, alkoxy interrupted by oxygen or carbonyl, alkylthio, amino, monosubstituted amino, or a substituted alkoxy; R.sub.2 is hydrogen; R.sub.3 is hydrogen, halogen, amino, alkylamino, dialkylamino, alkanoylamino, or nitro; R.sub.4 is hydrogen, halogen, nitro, sulfamoyl, alkylsulfamoyl, or dialkylsulfamoyl; or any two adjacent groups of the R.sub.1, R.sub.2, R.sub.3 and R.sub.4 may combine to form alkylenedioxy, and the remaining two groups are each hydrogen; R.sub.5 is hydrogen or alkyl; X is alkylene; m and n are each 1 or 2; provided that at least one of the groups R.sub.2, R.sub.3 and R.sub.4 is other than hydrogen, and acid addition salts, quaternary ammonium salts and N-oxide derivatives thereof, processes for preparation thereof, and pharmaceutical composition containing the same. Said compounds, salts and N-oxide derivatives thereof show excellent gastrointestinal motility enhancing activity.
化合物的公式为:##STR1## 其中R是氢,烷氧羰基,苄氧羰基,杂环芳基烷基,苯基烯基或--T--(Y).sub.p --R.sub.6(其中T是单键或烷基,Y是氧,硫或羰基,R.sub.6是苯基,取代苯基,萘基或二苯甲基,p为0或1,但当T为单键时,p为0);R.sub.1是卤素,羟基,烷氧基,环烷氧基,烯基氧基,炔基氧基,被氧或羰基中断的烷氧基,烷基硫基,氨基,单取代氨基或取代烷氧基;R.sub.2是氢;R.sub.3是氢,卤素,氨基,烷基氨基,二烷基氨基,烷酰胺基或硝基;R.sub.4是氢,卤素,硝基,磺酰胺基,烷基磺酰胺基或二烷基磺酰胺基;或R.sub.1,R.sub.2,R.sub.3和R.sub.4中的任意两个相邻的基团可以结合形成烷二氧基,其余两个基团均为氢;R.sub.5是氢或烷基;X是烷基;m和n均为1或2;条件是R.sub.2,R.sub.3和R.sub.4中至少有一个基团不是氢,以及其酸加成盐,季铵盐和N-氧化物衍生物,制备方法和包含它们的制药组合物。这些化合物,盐和N-氧化物衍生物表现出优异的胃肠动力增强活性。